{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:55:10Z","timestamp":1784138110156,"version":"3.55.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T00:00:00Z","timestamp":1679356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12325-023-02490-5","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T18:02:59Z","timestamp":1679421779000},"page":"2509-2514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-8283","authenticated-orcid":false,"given":"Axel","family":"De Greef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Dominique","family":"Ghislain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"de Montjoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Baeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,21]]},"reference":[{"issue":"10302","key":"2490_CR1","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(21)00438-4.","journal-title":"Lancet"},{"issue":"4","key":"2490_CR2","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1104a144","volume":"11","author":"S Schneider","year":"2021","unstructured":"Schneider S, Li L, Zink A. The new era of biologics in atopic dermatitis: a review. Dermatol Pract Concept. 2021;11(4): e2021144. https:\/\/doi.org\/10.5826\/dpc.1104a144.","journal-title":"Dermatol Pract Concept"},{"issue":"10290","key":"2490_CR3","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2150. https:\/\/doi.org\/10.1016\/S0140-6736(21)00588-2.","journal-title":"Lancet"},{"issue":"10302","key":"2490_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"398","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;398(10302):746. https:\/\/doi.org\/10.1016\/S0140-6736(21)00589-4.","journal-title":"Lancet"},{"issue":"4","key":"2490_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","volume":"158","author":"EL Simpson","year":"2022","unstructured":"Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404\u201313. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0029.","journal-title":"JAMA Dermatol"},{"key":"2490_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.10.034","author":"J Vanlerberghe","year":"2022","unstructured":"Vanlerberghe J, Dezoteux F, Martin C, et al. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.10.034.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2490_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40268-022-00396-1","volume":"22","author":"A Chiricozzi","year":"2022","unstructured":"Chiricozzi A, Gori N, Narcisi A, et al. Effectiveness and safety of upadacitinib in the treatment of moderate-severe atopic dermatitis: a multicentric, prospective, real-world, cohort study. Drugs R D. 2022;22(3):245\u201352. https:\/\/doi.org\/10.1007\/s40268-022-00396-1.","journal-title":"Drugs R D"},{"issue":"10","key":"2490_CR8","doi-asserted-by":"publisher","first-page":"e832","DOI":"10.1111\/jdv.18311","volume":"36","author":"G Feraru","year":"2022","unstructured":"Feraru G, Nevet MJ, Samuelov L, et al. Real-life experience of upadacitinib for the treatment of adult patients with moderate-to-severe atopic dermatitis\u2014a case series. J Eur Acad Dermatol Venereol. 2022;36(10):e832\u20133. https:\/\/doi.org\/10.1111\/jdv.18311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"2490_CR9","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1111\/jdv.18137","volume":"36","author":"M Napolitano","year":"2022","unstructured":"Napolitano M, Fabbrocini G, Genco L, Martora F, Potestio L, Patruno C. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497\u20138. https:\/\/doi.org\/10.1111\/jdv.18137.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6S","key":"2490_CR10","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1097\/DER.0000000000000958","volume":"33","author":"JJ Pereyra-Rodriguez","year":"2022","unstructured":"Pereyra-Rodriguez JJ, Herranz P, Figuras-Nart I, et al. Upadacitinib for the treatment of atopic dermatitis in a Spanish cohort-real life: fifty-two-week follow-up results. Dermatitis. 2022;33(6S):S124\u20137. https:\/\/doi.org\/10.1097\/DER.0000000000000958.","journal-title":"Dermatitis"},{"issue":"11","key":"2490_CR11","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/1346-8138.16549","volume":"49","author":"T Hagino","year":"2022","unstructured":"Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158\u201367. https:\/\/doi.org\/10.1111\/1346-8138.16549.","journal-title":"J Dermatol"},{"issue":"2","key":"2490_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1001\/jamadermatol.2021.3023","volume":"158","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2022;158(2):219. https:\/\/doi.org\/10.1001\/jamadermatol.2021.3023.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"2490_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","volume":"158","author":"AM Drucker","year":"2022","unstructured":"Drucker AM, Morra DE, Prieto-Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol. 2022;158(5):523\u201332. https:\/\/doi.org\/10.1001\/jamadermatol.2022.0455.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"2490_CR14","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.1111\/jdv.17705","volume":"36","author":"G Licata","year":"2022","unstructured":"Licata G, Gambardella A, Tancredi V, et al. Face atopic dermatitis resistant to dupilumab: a case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol. 2022;36(2):e150\u20132. https:\/\/doi.org\/10.1111\/jdv.17705.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02490-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02490-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T19:15:18Z","timestamp":1682450118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02490-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,21]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2490"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02490-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,21]]},"assertion":[{"value":"30 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}